Travere Therapeutics, Inc. 8-K

What Happened
Travere Therapeutics (filed 8-K on July 9, 2026) announced that Chief Accounting Officer and Principal Accounting Officer Sandra Calvin notified the company on July 6, 2026 that she will retire following the filing of the company’s Annual Report on Form 10-K, expected in February 2027. The company expects Vice President, Controller John Torell, CFA, CPA, to succeed Ms. Calvin as CAO and PAO, and the Board is expected to appoint him to those roles before the retirement to allow an orderly transition.

Key Details

• Filing: Form 8-K filed July 9, 2026 (Item 5.02 — officer departure/election).
• Retirement notice date: July 6, 2026; expected Retirement Date: after the 2026 Form 10-K filing (expected February 2027).
• Successor: John Torell — with Travere since 2021; Vice President, Controller since 2023; responsible for accounting operations, financial and SEC reporting, technical accounting, and internal controls.
• Background: Torell held senior finance roles at Pacific Life (1997–2019) and was an Audit Manager at Deloitte; he is a CFA and CPA and holds a B.A. in Economics-Business from UCLA.

Why It Matters
This is a planned, disclosed leadership transition in Travere’s finance and SEC-reporting functions. Naming an internal successor (the Controller) and planning an appointment before the retirement aims to preserve continuity in financial reporting and internal controls, which are material to investors because they affect the company’s financial statement preparation and SEC filings. The 8-K also contains customary forward-looking statements about the timing and execution of the transition.